Sangamo BioSciences CEO Sells $282,250 in Stock (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) CEO Edward Lanphier II sold 25,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $11.29, for a total transaction of $282,250.00. Following the transaction, the chief executive officer now directly owns 330,000 shares of the company’s stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Separately, analysts at Zacks upgraded shares of Sangamo BioSciences (NASDAQ:SGMO) from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 30th. They now have a $10.50 price target on the stock.
One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $16.70.
Sangamo BioSciences (NASDAQ:SGMO) traded up 4.82% during mid-day trading on Wednesday, hitting $11.09. 3,262,737 shares of the company’s stock traded hands. Sangamo BioSciences has a one year low of $4.92 and a one year high of $11.48. The stock has a 50-day moving average of $10.21 and a 200-day moving average of $9.28. The company’s market cap is $600.0 million.
Sangamo BioSciences (NASDAQ:SGMO) last released its earnings data on Wednesday, July 24th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.12) by $0.02. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $4.77 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. The company’s quarterly revenue was up 50.0% on a year-over-year basis. On average, analysts predict that Sangamo BioSciences will post $-0.44 earnings per share for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.